Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Parmiani

Showing results (231-240 of 301) with videos related to

Pageof 31
Sort By:
International Journal of Cancer|December 2, 1991
Human allogeneic melanoma-reactive T-helper lymphocyte clones: functional analysis of lymphocyte-melanoma interactionsM Radrizzani, B Benedetti, C Castelli, et al.
Tumori|October 31, 1988
A new procedure for large scale production and freezing of lymphokine activated killer (LAK) cells to be used in adoptive immunotherapy of cancerC Gambacorti-Passerini, M Radrizzani, L Rivoltini, et al.
The Journal of Experimental Medicine|July 1, 1993
Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gammaA Stoppacciaro, C Melani, M Parenza, et al.
Experimental and Clinical Immunogenetics|January 1, 1985
In vivo reexpression of H-2 antigens in B16 melanoma cellsP L Lollini, M P Colombo, C De Giovanni, et al.
Molecular and Cellular Biology|September 1, 1996
HOXB7 constitutively activates basic fibroblast growth factor in melanomasA Caré, A Silvani, E Meccia, et al.
International Journal of Cancer|March 15, 1982
Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c miceG Parmiani, M L Sensi, G Carbone, et al.
Tumori|December 31, 1987
A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effectsR Marolda, F Belli, A Prada, et al.
Journal of Immunogenetics|October 1, 1983
Impaired H-2 expression in B16 melanoma variantsP Nanni, M P Colombo, C De Giovanni, et al.
Cancer Research|February 1, 1996
Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cellsM Vagliani, M Rodolfo, F Cavallo, et al.
Cancer Immunology, Immunotherapy : CII|July 19, 2001
Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytesA Mazzocchi, C Melani, L Rivoltini, et al.
Pageof 31

Showing results (231-240 of 301) with videos related to

Sort By:
Pageof 31
International Journal of Cancer|December 2, 1991
Human allogeneic melanoma-reactive T-helper lymphocyte clones: functional analysis of lymphocyte-melanoma interactionsM Radrizzani, B Benedetti, C Castelli, et al.
Tumori|October 31, 1988
A new procedure for large scale production and freezing of lymphokine activated killer (LAK) cells to be used in adoptive immunotherapy of cancerC Gambacorti-Passerini, M Radrizzani, L Rivoltini, et al.
The Journal of Experimental Medicine|July 1, 1993
Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gammaA Stoppacciaro, C Melani, M Parenza, et al.
Experimental and Clinical Immunogenetics|January 1, 1985
In vivo reexpression of H-2 antigens in B16 melanoma cellsP L Lollini, M P Colombo, C De Giovanni, et al.
Molecular and Cellular Biology|September 1, 1996
HOXB7 constitutively activates basic fibroblast growth factor in melanomasA Caré, A Silvani, E Meccia, et al.
International Journal of Cancer|March 15, 1982
Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c miceG Parmiani, M L Sensi, G Carbone, et al.
Tumori|December 31, 1987
A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effectsR Marolda, F Belli, A Prada, et al.
Journal of Immunogenetics|October 1, 1983
Impaired H-2 expression in B16 melanoma variantsP Nanni, M P Colombo, C De Giovanni, et al.
Cancer Research|February 1, 1996
Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cellsM Vagliani, M Rodolfo, F Cavallo, et al.
Cancer Immunology, Immunotherapy : CII|July 19, 2001
Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytesA Mazzocchi, C Melani, L Rivoltini, et al.
Pageof 31